INTRODUCTION
• NICE and the SMC are health technology bodies that issue guidance on whether health technologies should be adopted by their respective health systems (NICE: England and Wales, SMC: Scotland) based upon their clinical and cost effectiveness, with the Incremental Cost Effectiveness Ratio as a key criteria for both.
• This research aims to compare how success rate varies by manufacturer.
RESULTS

NICE recommendations by manufacturer
• 216 NICE STA appraisals were identified by 52 manufacturers, 66% were "approved" -defined as "recommended" or "optimised".
• The three manufacturers who made the most frequent NICE submissions were:
• Roche (30, 57% approved),
• Novartis (20, 45% approved)
• Janssen-Cilag (14, 71% approved).
• The most successful (with ≥5 appraisals) were • Boehringer Ingelheim (10, 100% approved)
• Merck Sharp and Dohme (10, 80% approved)
• The least successful (with ≥5 appraisals) were • Novartis (20, 45% approved) • Celgene (6, 50% approved).
SMC recommendations by manufacturer
• 1255 SMC appraisals were identified by 165 different manufacturers, 61% were "approved" -defined as "accepted" or "restricted".
• The three manufacturers who made the most frequent SMC submissions were:
• Novartis (92, 57% approved), • Roche (67, 66% approved), and • Merck Sharp and Dohme (62, 79% approved).
• The most successful (with ≥10 appraisals) were • Astellas (13, 92% approved) • Boehringer Ingelheim (31, 90% approved)
• The least successful (with ≥10 appraisals) were • Amgen (18, 17% approved)
• Menarini (11, 18% approved).
• There was no significant correlation between the number of SMC and NICE appraisals and their success rates.
METHODS
• All NICE STA and SMC appraisal outcomes were extracted from the NICE and SMC websites up to 31st November 2015.
• The drug, manufacturer, and outcome were extracted.
• Statistical analyses were performed using Pearson's correlation coefficient.
CONCLUSIONS
• There is a wide range of NICE and SMC acceptance rates between companies, but success rates do not correlate with the number of submissions a company makes, suggesting that this difference may be reflected by the distinct portfolios of drugs of different companies and/or their pricing policies. 
